natgillin/translations-raw huggingface dataset:
However, in animal experiments these mutations confer cross resistance to all three echinocandins and therefore such isolates are classified as echinocandin resistant until further clinical experience are obtained concerning anidulafungin.
Vendar so z eksperimenti na živalih pokazali, da te mutacije prenašajo navzkrižno odpornost na vse tri ehinokandine, zato so take izolate razvrstili kot odporne proti ehokandinom, dokler ne pridobijo dodatnih kliničnih izkušenj z anidulafunginom.
However, in another clinical study which evaluated reactogenicity in children 3 to 9 years who received two adult (i.e.
Toda v drugi klinični študiji, ki je ocenjevala reaktogenost pri otrocih, starih od 3 do 9 let po dveh odmerkih (tj.
However, in clinical trials it has been observed that patients who tolerate doses of 21.6 μg/day following slow titration over a 3 to 4-week period, generally tolerate higher doses up to 48.0 μg/day.
V kliničnih študijah je bilo ugotovljeno, da bolniki, ki ob počasni 3- do 4-tedenski titraciji prenesejo dnevni odmerek 21,6 µg/dan, v splošnem prenesejo tudi višje odmerke do 48,0 µg/dan.
However, in combining with platinum agents, there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on day 1 or 5 of the topotecan dosing.
Pri sočasni uporabi s spojinami platine pa lahko pride do značilne interakcije, ki je odvisna od zaporedja dajanja zdravil, in sicer od tega ali boste uporabili zdravilo s platino na 1. ali na 5. dan odmerjanja topotekana.
However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (> 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (> 0,1 IU/ml) 3–4 tedne po enkratnem osnovnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem osnovnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion (>0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3-4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion (>0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of seronegative dogs did not show seroconversion (>0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Pri ljudeh pa uporaba sevoflurana zveča tako intenzivnost kot trajanje živčnomišične blokade, inducirane z nedepolarizirajočimi mišičnimi relaksanti
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Pri ljudeh pa uporaba sevoflurana zveča tako intenzivnost kot trajanje živčnomišične blokade, inducirane z nedepolarizirajočimi mišičnimi relaksanti.
However, in individuals who are already infected with one or more of the vaccine HPV types, Silgard can still protect against diseases associated with the other HPV types in the vaccine.
Vendar pa lahko cepivo Silgard osebe, ki so že okužene z enim ali več tipi HPV, ki jih vsebuje cepivo, še vedno ščiti pred boleznimi, ki so povezane z ostalimi tipi HPV v cepivu.
However, in one of these trials, a fixed-dose trial, there was a significant dose- response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).
Toda v enem od teh preskušanj (preskušanje s fiksnim odmerkom) je pri bolnikih, ki so prejemali aripiprazol, za cerebrovaskularne neželene učinke obstajal pomemben odnos med odmerkom in odzivom (glejte poglavje 4.8).
However, in patients receiving dabigatran, a clinically relevant interaction cannot be excluded when combined with clarithromycin.
Toda pri bolnikih, ki prejemajo dabigatran v kombinaciji s klaritromicinom, klinično pomembne interacije ne moremo izključiti.
However, in patients with FL the addition of Gazyvaro to bendamustine delayed the time to worsening of health-related quality of life as measured by the FACT-Lym TOI score by 2.2 months (median 5.6 versus 7.8 months for B and G+B respectively HR  0.83; 95% CI: 0.60, 1.13).
Vendar je pri bolnikih s FL dodatek zdravila Gazyvaro bendamustinu podaljšal čas do poslabšanja zdravstvene kakovosti življenja, merjene z oceno FACT- Lym TOI, za 2,2 meseca (mediana 5,6 meseca z bendamustinom in 7,8 meseca z G + B; RO  0,83, 95-% IZ: 0,60; 1,13).
However, in phase I clinical trials, a limited number of patients were treated with daily doses of up to 1000 mg.
So pa v kliničnih preskušanjih I. faze manjše število bolnikov zdravili z dnevnimi odmerki do 1000 mg.
However, in Phase III trials in Parkinson’s disease patients no clinically meaningful influence of body weight on the therapeutic effect and tolerability of MIRAPEXIN prolonged-release tablets was detected.
Toda v preskušanjih III. faze pri bolnikih s Parkinsonovo boleznijo niso zasledili klinično pomembnega vpliva telesne mase na terapevtski učinek in prenašanje MIRAPEXIN tablet s podaljšanim sproščanjem.
However, in Phase III trials in Parkinson’s disease patients no clinically meaningful influence of body weight on the therapeutic effect and tolerability of pramipexole prolonged-release tablets was detected.
Toda v preskušanjih III. faze pri bolnikih s Parkinsonovo boleznijo niso zasledili klinično pomembnega vpliva telesne mase na terapevtski učinek in prenašanje pramipeksol tablet s podaljšanim sproščanjem.
However, in Phase III trials in Parkinson’s disease patients no clinically meaningful influence of body weight on the therapeutic effect and tolerability of SIFROL prolonged-release tablets was detected.
Toda v preskušanjih III. faze pri bolnikih s Parkinsonovo boleznijo niso zasledili klinično pomembnega vpliva telesne mase na terapevtski učinek in prenašanje SIFROL tablet s podaljšanim sproščanjem.
However, in post-marketing experience very rare cases of atrial flutter with 1:1 atrioventricular conduction are observed.
Vendar pa so v obdobju po začetku trženja zdravila v zelo redkih primerih opazili atrijsko undulacijo z atrioventrikularnim prevajanjem 1:1.
However, in repeat-dose toxicity studies in rats and dogs, no histopathological findings were noted on reproductive organs (see section 5.3).
Pri študijah toksičnosti s ponavljajočimi se odmerki pri podganah in psih niso opazili histopatoloških sprememb na reproduktivnih organih (glejte poglavje 5.3).
However, in repeated-dose toxicity studies performed in rats and monkeys, effects on female fertility were observed in the form of follicular atresia, degeneration of corpora lutea, endometrial changes in the uterus and decreased uterine and ovarian weights at clinically relevant systemic exposure levels.
So pa v študijah toksičnosti ponavljajočih se odmerkov pri podganah in opicah, ob klinično pomembni sistemski izpostavljenosti, ugotovili učinke na plodnost samic, ki so se kazali kot atrezija foliklov, degeneracija rumenih telesc, spremembe endometrija v maternici in zmanjšanje mase maternice in jajčnikov.
However, in safety laboratory trials, the use of the vaccine in males proved to be safe.
Varnostni laboratorijski testi so dokazali, da je uporaba cepiva COXEVAC pri samcih varna.
However, in some cases, especially for younger patients, shorter dose intervals or higher doses may be necessary.
V nekaterih primerih, še posebej pri mlajših bolnikih, bodo morda potrebni krajši presledki med odmerki ali pa večji odmerki.
However, in some cases, especially for younger patients, shorter dose intervals or higher doses may be necessary.
V nekaterih primerih, še posebej pri mlajših bolnikih, morajo biti presledki med odmerki krajši ali pa odmerki večji.
However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation.
Vendar pa pri nekaterih bolnikih, okuženih s HIV–1, upad očistka kreatinina ni povsem izzvenel, kljub prekinitvi dizoproksiltenofovirata.
However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil fumarate discontinuation.
Vendar pa pri nekaterih bolnikih s HIV–1 upad očistka kreatinina ni povsem izzvenel kljub prekinitvi zdravljenja z dizoproksiltenofovirijevim fumaratom.
However, in some patients a rash, which appears as a blistering skin reaction, can be severe or life-threatening (Stevens-Johnson syndrome and toxic epidermal necrolysis) and deaths have been recorded.
Pri nekaterih bolnikih pa je lahko izpuščaj, kadar se pojavi kot mehurjasta kožna reakcija, hud ali življenjsko nevaren (Stevens-Johnsonov sindrom in toksična epidermalna nekroliza); zabeležili so že tudi smrtne izide.
However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil fumarate discontinuation.
Vendar pa pri nekaterih bolnikih upad očistka kreatinina ni povsem izzvenel, kljub prekinitvi dizoproksiltenofovirijevega fumarata.
However, in study US301 no significant differences were observed between leflunomide and methotrexatein the primary efficacy parameters.
V študiji US301 pa se parametri primarne učinkovitosti med leflunomidom in metotreksatom niso značilno razlikovali.
However, in the absence of understanding the association between maternal toxicity and developmental effect, the relevance to human safety cannot be addressed.
Vendar pa zaradi pomanjkanja razumevanja povezanosti med toksičnostjo za mater in učinkom na razvoj ne moremo dati podatkov za varnost pri človeku.
However, in the case of an accidental overdose, your doctor will start appropriate supportive treatment and will check you for changes in the number of blood cells, and for gastrointestinal symptoms (e.g. diarrhoea, nausea [feeling sick], vomiting).
Vendar pa bo v primeru nenamernega prevelikega odmerjanja zdravnik začel z ustreznim podpornim zdravljenjem in preveril morebitne spremembe števila krvnih celic in ali imate prebavne težave (npr. driska, navzea [siljenje na bruhanje], bruhanje).
However, in the case this needle size would not be available, a 21-G needle might be used.
Če ta velikost igle ni na voljo, se lahko uporabi igla 21-G.
However, in the event that transient hypotension (low blood pressure) does occur, symptomatic treatment, e.g. fluid therapy, should be provided.
Vendar pa je v primeru prehodne hipotenzije (nizkega krvnega tlaka) potrebno simptomatsko zdravljenje, npr. zdravljenje s tekočino.
However, in the event that transient hypotension does occur, symptomatic treatment, e.g. fluid therapy, should be provided.
Vendar pa je v primeru morebitnih kliničnih znakov hipotenzije potrebno simptomatsko zdravljenje, npr. zdravljenje s tekočino.
However, in the main multiple myeloma and myelodysplastic syndromes registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake.
Vendar pa so v glavnih registracijskih preskušanjih pri bolnikih z diseminiranim plazmocitomom in mielodisplastičnimi sindromi, kjer so ugotavljali učinkovitost in varnost lenalidomida, zdravilo dajali ne glede na vnos hrane.
However, in the pivotal multiple myeloma registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake.
Vendar pa so v osrednjih registracijskih preskušanjih pri bolnikih z diseminiranim plazmocitomom, kjer so ugotavljali učinkovitost in varnost lenalidomida, zdravilo dajali ne glede na vnos hrane.
However, in the presence of an inhibitor the doses required are variable and must be adjusted according to clinical response and monitoring of plasma factor VIII activity.
Ob prisotnosti inhibitorja so potrebni odmerki različni in jih je treba prilagajati glede na klinični odgovor in spremljati aktivnost faktorja VIII v plazmi.
However, in the subsequent 4 week randomised withdrawal phase of the study (Phase 2), the effect of aliskiren overlapped with the effects observed in patients switched to placebo in all dose groups (low, p=0.8894; mid, p=0.9511; high, p=0.0563).
V nadaljnjem 4-tedenskem randomiziranem obdobju odtegnitve (v 2. obdobju v študiji) pa se je pokazalo, da učinek aliskirena ni bistveno drugačen od učinka placeba, kar so opažali pri bolnikih, ki so prešli na uporabo placeba v vseh odmernih skupinah (pri nizkih odmerkih p=0,8894, pri srednje visokih odmerkih p=0,9511 in pri visokih odmerkih p=0,0563).
However, in the third study, patients with wild-type KRAS only survived overall for 16.3 months when Erbitux was added to the another oxaliplatin-based treatment similar to FOLFOX, compared with 18.2 months when the oxaliplatin-based treatment was used alone. the first study in patients who had taken chemotherapy before did not look at RAS mutations, but in the other two studies, patients with wild-type KRAS in their tumours lived for longer without their disease getting worse when Erbitux was added to their treatment.
Vendar pa je bilo v tretji študiji celokupno preživetje bolnikov z divjim tipom gena KRAS le 16,3 meseca, kadar je bilo zdravilo Erbitux dodano zdravljenju z oksaliplatinom, podobnemu zdravljenju FOLFOX, v primerjavi s 18,2 meseca, če je bilo zdravljenje z oksaliplatinom uporabljeno samostojno; v prvi študiji, izvedeni pri bolnikih, ki so predhodno že prejemali kemoterapijo, niso opazovali mutacij gena RAS, v drugih dveh študijah pa je pri bolnikih s tumorji z divjim tipom gena KRAS, ki so prejemali zdravilo Erbitux kot dodatek k zdravljenju, do poslabšanja bolezni prišlo pozneje.
However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
V celoti pa razpoložljivi podatki ne omogočajo dokončnega sklepa o tveganju srčne za srčne ishemije.(glejte poglavje 4.8).
However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
V celoti pa razpoložljivi podatki ne omogočajo dokončnega sklepa o tveganju za srčne (glejte poglavje 4.8).
However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
V celoti pa razpoložljivi podatki ne omogočajo dokončnega sklepa o tveganju za srčne ishemije (glejte poglavje 4.8).
However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
V celoti pa razpoložljivi podatki ne omogočajo dokončnega sklepa o tveganju za srčne ishemije. (glejte poglavje 4.8).
However, in these cases the initially reconstituted solution of Voncento should not be diluted any further.
Vendar pa v tem primeru prvotno pripravljene raztopine zdravila Voncento ne smemo dodatno redčiti.
However, in these patients, a starting dose higher than 100 micrograms may be considered.
Začetni odmerek zdravila pri teh bolnikih je lahko višji od 100 mikrogramov.
However, in those with an artificial lens in the affected eye or who previously have not responded to or are unsuitable for other non-corticosteroid treatments, the benefits of Ozurdex were considered to outweigh the risks.
Vendar je menil, da so koristi zdravila Ozurdex pri bolnikih z umetno lečo v prizadetem očesu ali bolnikih, ki se predhodno niso odzvali na druge oblike zdravljenja s kortikosteroidi ali te za njih niso bile primerne, večje od tveganj.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
Zaradi potencialnih tveganj, povezanih s hudo levkocitozo, pa je med zdravljenjem s filgrastimom potrebno redno opravljati meritve števila belih krvničk.
However, in vitro granulocyte function tests did not show significant changes when the sulesomab was added.
Vendar pa in vitro funkcijski testi granulocitov po dodatku sulezomaba niso pokazali signifikantne spremembe.
However, in vitro studies in human liver microsomes followed by physiologically-based pharmacokinetic modelling indicate that the blood concentrations achieved after a 175 mg dose of temsirolimus most likely leads to relevant inhibition of CYP3A4/5 (see section 5.2).
Vendar študije in vitro na humanih jetrnih mikrosomih, ki jim je sledilo farmakokinetično modeliranje na osnovi fizioloških lastnosti kažejo, da so koncentracije v krvi, dosežene po 175- miligramskem odmerku temsirolimusa, povzročile pomembno zaviranje CYP3A4/5 (glejte poglavje 5.2).
However, in vitro tafamidis meglumine inhibits the efflux transporter BCRP (breast cancer resistant protein) with IC50=1.16 µM and may cause drug-drug interactions at clinically relevant concentrations with substrates of this transporter (e.g. methotrexate, rosuvastatin, imatinib).
Vendar pa tafamidis meglumin in vitro zavira izločevalni prenašalec BCRP (BCRP – Breast Cancer Resistance Protein) z vrednostjo IC50 = 1,16 µM in lahko pri klinično pomembnih koncentracijah povzroči medsebojna delovanja s substrati tega prenašalca (npr. metotreksatom, rosuvastatinom, imatinibom).
However, in-use stability has been demonstrated for 3 hours at 2°C - 8°C.
Stabilnost po pripravi je dokazana za 3 ure pri temperaturi od 2 °C do 8 °C.
However, in-use stability has been demonstrated for 30 minutes when stored at 20C – 25C.
Dokazano je bilo, da je rekonstituirano cepivo, če ga hranimo pri temperaturi 20 ºC - 25 ºC, stabilno 30 minut.
However, individuals should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate.
Prejemnike je kljub temu potrebno opozoriti, da se lahko v času zdravljenja z emtricitabinom in dizoproksiltenofovirijevim fumaratom pojavi omotičnost.
However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy.
Vendar lahko intenziviranje insulinskega zdravljenja s hitrim izboljšanjem urejenosti glikemije spremlja prehodno poslabšanje diabeticne retinopatije.
However, interactions with, MATE1 and OCT2 substrates cannot be excluded.
Vendar medsebojnih delovanj s substrati MATE1 in OCT2 ni mogoče izključiti.
However, interferon alfa-2b may cause sleepiness, tiredness or confusion.
Vendar pa interferon alfa-2b lahko povzroči utrujenost, zaspanost ali zmedenost.
However, interpretive breakpoints for caspofungin have not been approved by EUCAST.
Vendar pa interpretacijskih kriterijev za kaspofungin EUCAST ni odobril.
However, investigator should be strongly requested to obtain a recent sample for determination of the RET status as often as possible, even in patients previously tested at an earlier stage of their disease.
Kljub temu je treba od raziskovalca odločno zahtevati čim bolj pogosto pridobivanje svežega vzorca za določitev statusa RET, celo pri bolnikih, ki so že bili preskušani v bolj zgodnji stopnji razvoja njihove bolezni.
However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Mogoče pa je pričakovati, da bo cepljenje preprečilo hepatitis D, saj se hepatitis D (ki ga povzroča agens delta) ne pojavi v odsotnosti okužbe s hepatitisom B.
However, it concluded that the medicine should only be considered for use as ‘last line’ therapy, when no other protease inhibitors are predicted to work.
Kljub temu pa je zaključil, da je treba zdravilo obravnavati le kot „zadnjo možnost“ zdravljenja, ko se predvideva, da noben drug zaviralec proteaze ne bo deloval.
However, it has not been possible to fully estimate exposure margins achieved for sofosbuvir in the rat relative to the exposure in humans at the recommended clinical dose (see section 5.3).
Vendar pa ni bilo povsem oceniti mogoče meja izpostavljenosti pri podganah, doseženih pri sofosbuvirju, glede na izpostavljenost pri ljudeh, ki so prejemali priporočeni klinični odmerek (glejte poglavje 5.3).
However, it is advisable to wait and see how you feel after taking Filgrastim HEXAL and before driving or operating machinery.
Kljub temu je pred vožnjo ali upravljanjem s stroji priporočljivo počakati, da vidite, kako se po uporabi zdravila Filgrastim HEXAL počutite.
However, it is advisable to wait and see how you feel after taking Grastofil and before driving or operating machinery.
Vendar je priporočljivo počakati, da vidite, kako se boste po uporabi zdravila Grastofil počutili, preden začnete voziti ali upravljati stroje.
However, it is advisable to wait and see how you feel after taking Nivestim and before driving or operating machinery.
Kljub temu je pred vožnjo avtomobila ali upravljanjem strojev priporočljivo počakati, da vidite, kako se počutite po tem, ko vzamete zdravilo Nivestim.
However, it is advisable to wait and see how you feel after taking Zarzio and before driving or operating machinery.
Kljub temu je pred vožnjo ali upravljanjem s stroji priporočljivo počakati, da vidite, kako se po uporabi zdravila Zarzio počutite.
However, it is difficult to distinguish them from frequent complications occurring in premature babies and complications due to the disease.
Vendar pa je te neželene učinke težko ločiti od pogostih zapletov, ki se pojavljajo pri nedonošenčkih, in zapletov zaradi bolezni.
However, it is known that the biologic response-modifying properties of interferon beta-1b are mediated through its interactions with specific cell receptors found on the surface of human cells.
Znano pa je, da se tiste lastnosti interferona beta- 1b, ki spreminjajo biološki odziv, posredujejo prek njegovih interakcij s specifičnimi celičnimi receptorji na površini humanih celic.
However, it is known that the biological response-modifying properties of interferon beta-1b are mediated through its interactions with specific cell receptors found on the surface of human cells.
Znano pa je, da se tiste lastnosti interferona beta- 1b, ki spreminjajo biološki odziv, posredujejo prek njegovih interakcij s specifičnimi celičnimi receptorji na površini človeških celic.
However, it is not considered likely that NeoSpect will affect your ability to drive or to operate machinery.
Vendar je pri NeoSpectu le malo verjetno, da bo vplival na vaše sposobnosti za upravljanje vozil in strojev.
However, it is not known whether telmisartan was the cause.
Vzročna povezanost ni dokazana.
However, it is not necessary to keep bitches away from treated dogs following subsequent implantations, provided that the veterinary medicinal product is administered every 6 months.
Pod pogojem, da se zdravilo uporabi vsakih šest mesecev, po poznejših implantacijah psic ni treba več ločevati od tretiranih psov.